Traws Pharma reports Phase 2a ratutrelvir data and plans Q4 resubmission for flu drug
The US biotech says its oral COVID-19 antiviral matched PAXLOVID on symptom resolution in a 92-subject study, while tivoxavir marboxil remains under an FDA clinical hold.
Traws Pharma released its third-quarter results on 16 November 2026, alongside updates on its two lead antiviral programmes. The company reported final data from a Phase 2a study of ratutrelvir, its oral COVID-19 antiviral, and set out its plans for tivoxavir marboxil, a candidate for influenza prevention.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Traws Pharma, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.